Hemgenix (etranacogene dezaparvovec), an adeno-associated pathogen vector-based gene therapy, has been approved by the Food and Drug Administration for the medication of adults with Hemophilia B (congenital Factor IX deficiency) who've been currently receiving Factor IX prophylaxis therapy, have existing or heritage life-threatening internal bleeding, or have repeated, serious spontaneous bleeding episodes.
It will cost US$3.5 million for each dose, making it the most costly medication in the world. At first look, the price appears exorbitant, but a new examination of the drug's cost-effectiveness reveals that it is a rather 'fair' cost for what the medication does - at least in the United States.
The medication, known as Hemgenix, is a novel gene therapy medication for hemophilia B, a rare hereditary disorder that causes blood clotting problems.
The most dangerous signs are difficult-to-stop spontaneous and recurrent bleeding episodes.
Million-Dollar Cure for Hemophilia B
While a precise figure is challenging to come by, forecasts suggest that almost 8,000 males in the United States today suffer from lifelong conditions. The major medicine now used to cure hemophilia B within the United States provides patients with a vital coagulation factor, but its lifelong treatment costs are too expensive. In people who experience severe symptoms, a rigorous and costly treatment regimen is essential, one that might begin to lose effectiveness over time, according to an advocacy group, Hemo B.
Researchers now estimate that the adult life span for each individual with mild to chronic hemophilia B is between US$21 and $23 million. Treatment expenses in the UK are lower compared to the United States or other parts of Europe, but they nevertheless build up to hundreds of millions of euros per individual throughout their life.
Hemgenix, in contrast, is a once-only intravenous medication that is administered in a single dosage for a less expensive price. The product enters the body using a viral-based vector designed to transfer DNA to target cells in the liver. Cells then reproduce this genetic material, distributing the directions for a coagulation protein called Factor IX.
So far, two studies have been conducted to assess Hemgenix's effectiveness and safety. Researchers discovered enhanced Factor IX levels of activity in one trial of 54 individuals with severe or slightly severe hemophilia B, lowering the requirement for regular replacement medicines now offered to patients.
The United States Federal Drug Administration (FDA) has just approved a new treatment for a rare blood clotting disease, one with a hefty price tag. Per dose, it'll cost US$3.5 million, making it the most expensive drug anywhere in the world.
Hemgenix Gene Therapy
When patients received gene therapy, the research rate of uncontrolled bleeding decreased by more than 50 % opposed to their background rate. Migraine, flu-like manifestations, and enzyme increases in the liver were among the side effects, which should be closely examined by doctors in the future. For more than two decades, gene therapy treating hemophilia has been on the horizon. Despite advances in hemophilia therapy, the management and prevention of major bleeding can have a negative influence on an individual's overall well-being.
The clearance provides a new therapeutic option for people with hemophilia B and also marks significant advancements in the creation of novel medicines for those suffering from the high disease burden associated with this type of hemophilia. Although it is unclear whether such gene therapy treatment offers a solution for hemophilia B, the first findings are encouraging.
The FDA does have a special classification to encourage medical research for serious but uncommon illnesses such as hemophilia B. Hemgenix, for example, is designated as an "orphan medicine" since it will only be used to treat a tiny number of patients.
CSL Behring, the maker of Hemgenix, has been granted exclusivity to the US industry for another seven years as a result of this classification. The rewards used by the US administration to encourage scientific research are a good approach to accelerate innovation in uncommon diseases that might otherwise go unnoticed, yet this strategy is a double-edged sword.
Availability of the Medication in Leading Nations
It also implies that the US market bears the expense of maintaining pharma monopolies, while other countries with price controls receive the advantages of international research, as per the KHN report.
The United States pays two to six times as much for prescription pharmaceuticals as the rest of the globe. Another 'one shot' version of gene therapy to combat spinal muscular atrophy held the previous record for the most costly medicine. With an estimated cost of $2 million for each course, it has sparked intense discussion about how pharma firms support their operations.
Although many drug companies have used orphan drug classification to build medication monopolies over the last few decades, this latest product might be one situation where the program works for certain patients.
The initial expenses are undeniably high, but for those who are lucky to be covered by a supportive insurance provider, Hemgenix has the potential to save millions of dollars in medical bills while changing lives in unfathomable ways. The European Medicines Agency, as well as its equivalents in the UK and Australia, are now assessing the gene therapy medication for approval. It will be fascinating to learn how much Hemgenix medicine makers are permitted to charge in other regions of the world.
RELATED ARTICLE: 27-Year-Old Patient Receiving CRISPR Gene Therapy Dies, Sparking Concern in Scientific Community
Check out more news and information on Medicine and Health in Science Times.
